Percheron Therapeutics Limited has released a press release.
New data supports ATL1102s broader clinical potential
Filed with ASX ·
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- ANP to present new proteomics data at WMS Congress 2021
- ANP Updates on US Regulatory Plans for ATL1102 in DMD
- ANP and MCRI new R&D collaboration for ATL1102
- ATL1102 for DMD EMA PIP feedback and FDA regulatory progress
- US FDA Feedback on Type C Meeting for ATL1102 in the US
Later from Percheron Therapeutics
- Positive feedback received on Paediatric Investigation Plan
- Positive PDCO opinion and A$20m Placement
- Investor Presentation
- ATL1102 Toxicology Protocol submitted to US FDA
- Positive UK PIP Decision & PDCO opinion ratification by EMA
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics